The HMGB1 Knockout UM-UC-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population originating from the human bladder transitional cell carcinoma cell line UM-UC-3, featuring targeted disruption of the HMGB1 gene. This polyclonal model offers a heterogeneous loss-of-function system, avoiding clonal artifacts and enabling robust assessment of HMGB1-dependent phenotypes in a cancer-relevant background.
The host UM-UC-3 cell line is an established epithelial model of high-grade invasive bladder transitional cell carcinoma, widely employed in urologic oncology research. These adherent cells exhibit characteristic urothelial carcinoma morphology and harbor relevant genetic alterations, including mutations in TP53 and other tumor suppressors. This cell line retains key features of aggressive bladder cancer, such as anchorage-independent growth, invasive capacity, and expression of basal molecular markers, making it a pertinent platform for dissecting the roles of damage-associated molecular patterns like HMGB1.
HMGB1 is a highly conserved chromosomal protein that functions as a DNA chaperone, regulating transcription, chromatin remodeling, and DNA repair. Upon passive release from necrotic cells or active secretion in response to stress, HMGB1 acts as a prototypical DAMP, engaging the receptor for advanced glycation end-products (RAGE) and Toll-like receptor 4 (TLR4) to initiate intracellular signaling. Its upstream regulators include pro-inflammatory stimuli such as LPS, TNF-??, IFN-??, and reactive oxygen species, as well as transcription factors NF-??B, p53, and HIF-1??. Once activated, HMGB1 signaling converges on NF-??B and MAPK pathways, promoting the expression of pro-inflammatory cytokines (TNF-??, IL-6, IL-1??) and contributing to cellular proliferation, migration, and invasion. HMGB1 also interacts with TLR2, histones, p53, p73, CXCL12, and CXCR4, integrating extracellular stress with transcriptional responses. Representative pathway components downstream of HMGB1 include TLR4, MyD88, NF-??B, RAGE, MAPK, JNK, and MMP-9.
In bladder cancer, HMGB1 overexpression is correlated with advanced tumor stage, metastasis, and poor prognosis, reflecting its dual role in sustaining tumor cell-autonomous survival signals and modulating the tumor microenvironment. Disruption of HMGB1 in UM-UC-3 cells allows researchers to interrogate its contribution to malignant phenotypes, including enhanced proliferation, resistance to apoptosis, and epithelial?Cmesenchymal transition. Moreover, because HMGB1 is actively secreted by cancer cells and immune cells within the tumor stroma, this polyclonal knockout model facilitates the study of paracrine signaling networks that drive inflammation and immune evasion. The interplay between HMGB1 and RAGE/TLR4-mediated pathways is particularly relevant for understanding chemoresistance and identifying therapeutic vulnerabilities in urothelial carcinomas.
These polyclonal knockout cells are suited for diverse functional studies. HMGB1??s role in bladder cancer proliferation and invasion can be assessed using scratch wound and Matrigel invasion assays, with validation by immunofluorescence and Western blotting. Inflammatory signaling is evaluated via NF-??B reporter assays and cytokine ELISA measuring TNF-??, IL-6, and IL-1??. Co-immunoprecipitation examines HMGB1 interactions with RAGE, TLR4, and histones, and apoptosis (Annexin V) and chemosensitivity assays help define its contribution to drug resistance. Additionally, the model supports high-throughput screening against HMGB1-dependent pathways and investigation of upstream regulators such as LPS and TNF-??. For further technical details or custom applications, please contact Ascent Research.
